HSPD1 and Autoimmunity: Similarly, in a longitudinal pre- and post-therapy analysis, synovial HSPD1 expression was downmodulated selectively in patients with RA who had a good clinical response to rituximab, suggesting that the HSP60 autoimmunity might influence the clinical response to B cell–depleting therapy.